Drug Trial Radar · NCT07102251
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Sep 21, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose administration in healthy subjects and multiple-dose administration in overweight or obese subjects. The trial consists of two parts: Part A is a single ascending dose (SAD) study, planning to enroll 54 Chinese healthy subjects; Part B is a multiple ascending dose (MAD) study, planning to enroll 72 Chinese overweight or obese subjects.
Conditions
- Healthy Subjects
Interventions
HEC-007 injectionDrug
Single dose escalation of HEC-007 injection in healthy subjects
PlaceboDrug
Single dose of placebo in healthy adults
HEC-007 injectionDrug
Multiple dose escalation of HEC-007 injection in Overweight or Obese Subjects
PlaceboDrug
Multiple dose of placebo in Overweight or Obese Subjects
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: Screening period up to day 43/day 113
- The maximum plasma concentration (Cmax)Time frame: Post-dose at day 1 to day 43/day 113
- Time to maximum plasma concentration (Tmax)Time frame: Post-dose at day 1 to day 43/day 113
- Terminal half-life (t1/2)Time frame: Post-dose at day 1 to day 43/day 113
- Apparent clearance (CL/F)Time frame: Post-dose at day 1 to day 43/day 113
- Apparent volume of distribution (Vz/F)Time frame: Post-dose at day 1 to day 43/day 113
- Area Under the PlasmaConcentration-TimeCurve (AUC) of HEC-007Time frame: Post-dose at day 1 to day 43/day 113
- Changes from baseline in Body WeightTime frame: Baseline period up to day 43/day 113
- Changes from baseline in waist circumferenceTime frame: Baseline period up to day 43/day 113
- Changes from baseline in Fasting Plasma GlucoseTime frame: Baseline period up to day 43/day 113
- Changes from baseline in Fasting InsulinTime frame: Baseline period up to day 43/day 113
- Changes from baseline in fasting blood lipidsTime frame: Baseline period up to day 43/day 113
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Anhui Medical University is a Grade A Tertiary General
Hefei, Anhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.